Baroque Pharmaceuticals Private Limited

Baroque Pharmaceuticals Private Limited, established on November 23, 1993, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of March 2026, Baroque Pharmaceuticals has an authorized capital of ₹5.27 crore and a paid-up capital of ₹1.68 crore. The company employs between 200 and 500 staff members, reflecting its substantial presence in the pharmaceutical industry. (clodura.ai) Baroque Pharmaceuticals operates under the Corporate Identification Number (CIN) U24230GJ1993PTC020695, as registered with the Registrar of Companies, Ahmedabad. The company's official website is www.baroquepharma.com, providing comprehensive information about its products and services.

Baroque Pharmaceuticals operates multiple manufacturing facilities in India, with the primary plant located in Khambhat, Gujarat. This facility is approved by various regulatory authorities from Africa, South Asia, CIS, Latin America, Southeast Asia, Central Asia, and the Middle East. The company has undertaken assignments to obtain higher regulatory approvals, aiming to enhance its global market presence. Additionally, Baroque Pharmaceuticals has a manufacturing unit in Nigeria, further expanding its production capabilities. The facilities are certified by WHO-GMP and EU-GMP, ensuring compliance with international quality standards.

The leadership team at Baroque Pharmaceuticals is spearheaded by Chairman and Managing Director Mr. J.D. Patel, who has over 43 years of technical and strategic experience in the pharmaceutical industry. Other key executives include Mr. Lalit Saraswat, Director, with over 30 years of experience, and Mr. Pragnesh J. Patel, Director, possessing more than 20 years in the field. Mr. Jignesh Patel, Director, brings over 25 years of medical practice experience to the team. This diverse and experienced leadership team drives the company's strategic direction and operational excellence.

Baroque Pharmaceuticals has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are approved by regulatory authorities from these regions, facilitating market access and compliance with stringent quality standards. Baroque Pharmaceuticals has undertaken assignments to obtain higher regulatory approvals, aiming to enhance its global market presence. The company's commitment to quality and compliance is further demonstrated by its WHO-GMP and EU-GMP certifications, which are essential for market access in these regions.

Baroque Pharmaceuticals has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are approved by various regulatory authorities from these regions, facilitating market access and compliance with local standards. Additionally, Baroque Pharmaceuticals has undertaken assignments to obtain higher regulatory approvals, aiming to enhance its global market presence. The company's commitment to quality and compliance is further demonstrated by its WHO-GMP and EU-GMP certifications, which are essential for market access in these regions.

Baroque Pharmaceuticals has strategically diversified its operations across multiple geographic regions, including India, Africa, Latin America, Southeast Asia, and select developed markets. This diversification mitigates concentration risk and positions the company to leverage growth opportunities in various markets. The company's commitment to obtaining higher regulatory approvals underscores its strategic direction to enhance global market access and competitiveness. Baroque Pharmaceuticals' focus on quality manufacturing and compliance with international standards further strengthens its strategic position in the global pharmaceutical industry.

Baroque Pharmaceuticals' manufacturing facilities are approved by various regulatory authorities, including those from the United States. The company's commitment to obtaining higher regulatory approvals underscores its strategic direction to enhance global market access and competitiveness. Baroque Pharmaceuticals' focus on quality manufacturing and compliance with international standards further strengthens its strategic position in the global pharmaceutical industry.

Baroque Pharmaceuticals' manufacturing facilities are certified by WHO-GMP and EU-GMP, ensuring compliance with international quality standards. These certifications are essential for market access in regulated markets and reflect the company's commitment to quality manufacturing. The company's focus on obtaining higher regulatory approvals further demonstrates its dedication to enhancing global market presence and competitiveness.

Baroque Pharmaceuticals operates under the Corporate Identification Number (CIN) U24230GJ1993PTC020695, as registered with the Registrar of Companies, Ahmedabad. The company's manufacturing facilities are approved by various regulatory authorities, including those from India. Baroque Pharmaceuticals' commitment to obtaining higher regulatory approvals underscores its strategic direction to enhance global market access and competitiveness. The company's focus on quality manufacturing and compliance with international standards further strengthens its strategic position in the global pharmaceutical industry.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Baroque Pharmaceuticals. The company's commitment to quality manufacturing and compliance with international standards, as evidenced by its WHO-GMP and EU-GMP certifications, suggests a proactive approach to regulatory compliance. Additionally, Baroque Pharmaceuticals has undertaken assignments to obtain higher regulatory approvals, aiming to enhance its global market presence.

Baroque Pharmaceuticals operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. The company's focus on quality manufacturing, as evidenced by its WHO-GMP and EU-GMP certifications, positions it favorably in the market. Additionally, Baroque Pharmaceuticals' commitment to obtaining higher regulatory approvals demonstrates its strategic direction to enhance global market access and competitiveness. The company's diversified geographic presence across India, Africa, Latin America, Southeast Asia, and select developed markets further mitigates concentration risk and positions it to leverage growth opportunities in various regions.

Baroque Pharmaceuticals' key differentiators include its commitment to quality manufacturing, as evidenced by its WHO-GMP and EU-GMP certifications, and its strategic focus on obtaining higher regulatory approvals to enhance global market access. The company's diversified geographic presence across India, Africa, Latin America, Southeast Asia, and select developed markets further mitigates concentration risk and positions it to leverage growth opportunities in various regions. Additionally, Baroque Pharmaceuticals' focus on providing cost-effective medicines to the global population underscores its dedication to improving global health.

Baroque Pharmaceuticals is strategically positioned as a quality-focused pharmaceutical company committed to providing cost-effective medicines globally. The company's strategic direction includes obtaining higher regulatory approvals to enhance global market access and competitiveness. Baroque Pharmaceuticals' diversified geographic presence across India, Africa, Latin America, Southeast Asia, and select developed markets mitigates concentration risk and positions it to leverage growth opportunities in various regions. The company's focus on quality manufacturing, as evidenced by its WHO-GMP and EU-GMP certifications, further strengthens its strategic position in the global pharmaceutical industry.

Baroque Pharmaceuticals has demonstrated a consistent track record in pharmaceutical manufacturing, with a focus on quality and compliance with international standards. The company's manufacturing facilities are approved by various regulatory authorities, including those from India, Africa, South Asia, CIS, Latin America, Southeast Asia, Central Asia, and the Middle East. Baroque Pharmaceuticals' commitment to obtaining higher regulatory approvals underscores its strategic direction to enhance global market access and competitiveness. The company's diversified geographic